New study tracks Leuprorelin's Long-Term effects in rare muscle disease
NCT ID NCT03555578
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 23 times
Summary
This study is monitoring the long-term safety and effectiveness of the drug leuprorelin in people with spinal and bulbar muscular atrophy (SBMA), a rare muscle-weakening disease. Researchers will follow about 1,890 patients in routine medical care for up to 8 years, tracking side effects and serious events like pneumonia or death. The goal is to understand how well the drug works in real-world use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SPINAL AND BULBAR MUSCULAR ATROPHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Takeda Selected Site
RECRUITINGTokyo, Japan
Conditions
Explore the condition pages connected to this study.